Brain metastases from malignant melanoma

FORUM - Trends in Experimental and Clinical Medicine

Volumn 13, Issue 2, 2003, Pages 170-185

  Chiarion Sileni, Vanna ^a   Murr, Rita ^b   Pigozzo, Jacopo ^a   Sarti, Samanta ^b   Tomassi, Ottaviano ^a   Romanini, Antonella ^b  

^a Busonera Hospital   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Melanoma; Metastasis

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBAMAZEPINE; CISPLATIN; COTRIMOXAZOLE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOTEMUSTINE; GAMMA INTERFERON; INTERLEUKIN 2; OMEPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; SYNTHETIC PEPTIDE; TEMOZOLOMIDE; VINBLASTINE;

AUTOPSY; BLOOD TOXICITY; BRAIN EDEMA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MEGADOSE; HEADACHE; HUMAN; LEUKOPENIA; LYMPHATIC DRAINAGE; MELANOMA; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; QUALITY OF LIFE; RADIOSURGERY; REVIEW; SEIZURE; SYMPTOM; THROMBOCYTOPENIA; TUMOR CELL; BRAIN TUMOR; METASTASIS; PATHOLOGY; SKIN TUMOR;

BRAIN NEOPLASMS; HUMANS; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 33749008556     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Posner JB. Brain metastases, 1995. A brief review. J. Neurooncol. 1996; 27: 287-293.
2. Madjewicz S et al. Malignant melanoma brain metastases: review of Roswell Park Memorial Institute experience. Cancer 1984; 53: 2550-2552.
3. Byrne TN et al. Brain metastases from melanoma. J. Neurooncol. 1983; 1: 313-317.
4. Sampson JH et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 1998; 88: 11-20.
5. Bullard DE et al. Central nervous system metastases in malignant melanoma. Neurosurgery 1999; 8: 26-30.
6. Akslen LA et al. Metastatic distribution in malignant melanoma: a 30-year autopsy study. Invasion Metastasis 1987; 7: 253-263.
7. Barth A et al. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 1995; 181: 193-201,
8. Yu C et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radio-surgery. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 1277-1287.
9. Delattre JY et al. Distribution of brain metastases. Arch. Neurol. 1988; 45: 741-744.
10. Hwang T et al. Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer 1996; 77: 1551-1555.
11. Douglas JC and Margolin K. The treatment of brain metastases from malignant melanoma. Seminar. Oncol. 2002; 29: 518-524.
12. Davey P and O'Brien P. Disposition of cerebral metastases from malignant melanoma: implications for radiosurgery. Neurosurgery 1991; 28: 8-14.
13. Merimsky O et al. CNS metastases of malignant melanoma in interferon complete responders: clinical and radiological observations. J. Neurooncol. 1992; 12: 137-140,
14. Atkins MB et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, Vinblastine, temozolomide, interleukin-2, and IFN-alpha 2b in patients with metastastic melanoma. Clin. Cancer Res. 2002; 8: 3075-3781.
15. Schmittel A et al. CNS metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. Eur. J. Cancer 2003; 39: 476-480,
16. Nussbaum ES et al. Brain Metastases. Histology, Multiplicity, Surgery, and Survival. Cancer 1996; 78: 1781-1788.
17. Mandybur TI. Intracranial hemorrage caused by metastatic tumors, Neurology 1977; 27: 650-655.
18. Nutt SH and Patchell RA. Intracranial hemmorhage associated with primary and secondary tumors. Neurosurgery Clin. North Am. 1992; 3: 591-599.
19. Sze G et al. Detection of brain matastases. Comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. Am. J. Neuroradiol. 1990; 11:785-791.
20. Davis PC et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. Am. J. Neuroradiol. 1991; 12: 293-300.
21. Yuh WTC et al. The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastases. Am. J. Neuroradiol. 1995; 16:373-380.
22. Russel EJ et al. Multiple cerebral metastases: Detectability with Gd-DTPA enhanced MR imaging. Radiology 1987; 165: 609-617.
23. Hawighorst H et al. Serial MR imaging of intracranial metastases after radiosurgery. Magn. Reson. Imaging 1997; 15: 1121-1132.
24. Huber PE et al. Transient enlargement of contrast uptake on MRI after linear accelerator (LINAC) stereotactic radiosurgery for CNS metastases. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 1339-1349.
25. Rohren EM et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003; 226: 181-187.
26. Stas M et al. 18-FDG PET scan staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002; 12: 479-490.
27. Gaspar L et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) CNS metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37: 745-751.
28. Buchsbaum JC et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with CNS metastases from malignant melanoma. Cancer 2002; 94: 2265-2272.
29. Westphal M et al. Intracranial metastases: therapeutic options. Ann. Oncol. 2003: 14 (Suppl. 3): 4-10.
30. Patchell RA. The management of brain metastases. Cancer Treat. Rev. 2003; 29: 533-540.
31. Lisa M et al. Metastatic brain tumors. Cancer management: a multidisciplinary approach. Fifth edition 2001.
32. Crossen JR et al. Neurobehavioral sequelae of cranial irradiation in adults: e review of radiation-induced encephalopathy. J. Clin. Oncol. 1994; 12: 627-642.
33. Ellerhost J et al. Whole Brain irradiation for patients with metastatic melanoma: a Review of 87 cases. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49:93.
34. Robins HI et al. Combined modality treatment for central nervous system malignancies. Semin. Oncol. 2003; 4 (Suppl. 9): 11-22.
35. Young RF. Radiosurgery for the treatment of brain metastatic. Semin. Surg. Oncol. t998; 14: 70-78.
36. Mehta MP et al. Defining the role of radiosurgery in the managment of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24: 619-625.
37. Chougule PB et al. Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both. Int. J. Radiat. Oncol. Biol. Phys. 2000: 48, 114.
38. Sperduto PW et al. Preliminary report of RTOG-9508: A phase III trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2000: 48: 113 (abstr).
39. Sneed PK et al. A multi-institutional review of radiosurgery alone vs radiosurgery with WBRT as the initial management of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2003; 53: 519-526.
40. Weinberg JS et al. Surgical management of CNS metastases. Current Oncol. Rep. 2001; 3: 476-483.
41. Brega K et al. Surgical treatment of CNS metastases in malignant melanoma. Cancer 1990; 66: 2105 -2110.
42. Karakousis CP. Surgical treatment of malignant melanoma. Surg. Clin. North Am. 1996; 76: 1299-1312.
43. Konstadoulakis MM et al. Prognostic factors in malignant melanoma patients with solitary or multiple CNS metastases. Is there a role for surgery? J. Neurosurg. Sci. 2000; 44: 211-218.
44. Wronsky M and Arbit E. Surgical treatment of CNS metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 2000; 93: 9-18.
45. Patchell RA et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280: 1527-1529.
46. Mintz AH et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78: 1470-1476.
47. Patchell RA et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990; 3 22: 494-500.
48. Noordijik EM et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29: 711-717.
49. Hagen N et al. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990; 40: 158-160.
50. Skibber JM et al. Cranial irradiation after surgical excision of CNS metastases in melanoma patients. Ann. Surg. Oncol. 1996; 3: 118-113.
51. Schackert G et al. Surgical management of single and multiple brain metastases: results of a retrospective study. Onkologie 2001; 24: 246-255.
52. Sundaresan N et al. Reoperation for CNS metastases. J. Clin. Oncol. 1988; 6; 1241-1245.
53. Bindal RK et al. Reoperation for recurrent metastatic brain tumors. J. Neurosurg. 1995; 83: 600-604.
54. Hurst R et al. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J. Immunother. 1999; 22: 356-362.
55. Phuphanich S et al. Response of recurrent CNS metastases in malignant melanoma to 5-fluorouracil and interferon-α therapy. J. Neuroimag. 1994; 4: 114-116.
56. Schadendorf D et al. CNS metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma. J. Neuro. Oncol. 1993; 16: 77-79.
57. Guirguis LM et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with CNS metastases. J. Immunother. 2002; 25: 82-87.
58. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998; 4: 321-327.
59. Jacquillat C et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with Cerebral metastases. Cancer 1990; 66: 1873-1878.
60. Schallreuter KU et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother. Pharmacol. 1991; 29: 85-87.
61. Falkson CI et al. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest. New Drugs 1994; 12: 251-254.
62. Kleeberg UR et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicenter phase II trial of the EORTC-Melanoma Cooperative Group. Melanoma Res. 1995; 5: 195-200.
63. Avril MF et al. Combination chemotherapy of Dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother. Pharmacol. 1990; 27: 81,84.
64. Binder M et al. Fotemustine plus Dacarbazine in advanced stage III malignant melanoma. Eur. J. Cancer 1992; 28 A: 1814-1816.
65. Merimsky O et al. Fotemustine and DTIC combination in patients with disseminated malignant melanoma. Am. J. Clin. Oncol. 1992; 15: 84-86.
66. Chang J et al. A phase II study of the sequential administration of Dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur. J. Cancer 1994; 30 A: 2093-2095.
67. Baker SD et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 1999; 5: 309-317.
68. Newlands ES et al. Phase I trial of temozolomide. Br. J. Cancer 1992; 65: 287-291.
69. Middleton MR et al. Randomized phase III study of temozolomide versus Dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000; 18: 158-166.
70. Abrey LE et al. A phase II trial of temozolomide for patients with recurrent or progressive CNS metastases. J. Neurooncol. 2001; 53: 259-265.
71. Biasco G et al. Treatment of CNS metastases; of malignant melanoma with temozolomide. N. Engl. J. Med. 2001; 345: 621.
72. Bleehen NM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 1995; 13: 910-913.
73. Bafaloukos D et al. Temozolomide in combination with Docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 2002; 20: 420-425.
74. Ulrich J et al. Management of cerebral metastases from malignant melanoma: Results of a combined, simultaneous treatment with fotemustine and irradiation. J. Neurooncol. 1999; 43; 173-178.
75. Bröcker EB et al. Fotemustine, given simultaneously with total brain irradiation in multiple CNS metastases of malignant melanoma: report on a pilot study. Melanoma Res. 1996; 6:399-401.
76. Mornex F et al. A prospective randomized multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003; 13: 97-103.
77. Margolin K et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 2002; 128: 214-218.
78. Aamdal S et al. A phase III randomized trial of fotemustine (F) versus Dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without CNS metastases. Proc. Am. Soc. Clin. Oncol. 2002; 21: 341 (abs. 1361).
79. Paul MJ et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002; 12: 175-178.
80. Glantz MJ et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886-1893.
81. Byrne TN et al. Brain metastases from melanoma. J. Neurooncol. 1983, 1: 313-317.
82. Posner JB. Neurologic complications of cancer. Philadelphia. PA: FA. Davis 1995.
83. Batchelor T and De Angelis LM. Medical management of cerebral metastases. Neurosurgery Clin. North Am. 1996; 7: 435-446.
84. Vecht CJ et al. Dose-effect relationship of desamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8 and 16 mg/day. Neurology 1994, 44: 675-680.
85. Werk EE et al. Interference in the effect of dexamethasone by diphenyl hydantoin. N. Engl. J. Med. 1969; 281: 32-34.